Determination of clofazimine in leprosy patients by high-performance liquid chromatography

Journal of Analytical Toxicology

Volumn 27, Issue 6, 2003, Pages 377-380

  Queiroz, R H C ^a   Pereira, R C ^a   Gotardo, M A ^a   Cordeiro, D S ^a   Melchior Jr , E ^b  

^a Department of Clinical   (Brazil)

^b Regl S D O Clin Ribeirao Preto   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; CLOFAZIMINE; DAPSONE; DICHLOROMETHANE; MEDAZEPAM; METHANOL; RIFAMPICIN;

ACCURACY; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEPROSY; MALE; PH; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SPECTRAL SENSITIVITY;

EID: 0041932356     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/27.6.377     Document Type: Article

References (20)

1. V.C. Barry, J.V. Belton, and M.L. Conalty. A new series of phenazines with high antituberculous activity. Nature 179: 1013-1015 (1957).
2. J.C. Garrelts. CFZ: a review of its use in leprosy and mycobacterium avium complex infection. Ann. Pharmocother. 25: 525-531 (1991).
3. S.J. Yawalkar and W. Vischer. Lamprene (CFZ) in leprosy. Lepr. Rev. 50: 135-144 (1979).
4. J.P. Mackey and J. Barnes. CFZ in the treatment of discoid lupus reythematosus. Br. J. Dermatol. 91: 93-96 (1974).
5. G. Michaelsson, L. Molin, and S. Ohman. CFZ: a new agent for the treatment of pyoderma gangrenosum. Arch. Dermatol. 112: 344-349 (1976).
6. B. Kaplan, H. Trau, and E. Sofer. Treatment of pyoderma gangrenosum with CFZ. Int. J. Dermatol. 31: 591-593 (1992).
7. C.R. Hoorsburgh, Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324: 1332-1338 (1991).
8. C.A. Kemper, T. Meng, and J. Nussbaum. Treatment of mycobacterium avium complex bacteremia in AIDS with a four drug oral regimen. Ann. Intern. Med. 116: 466-472 (1992).
9. C.R. Horsburgh, Jr., J.A. Havlik, and D.A. Ellis. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am. Rev. Respir. Dis. 144: 557-559 (1991).
10. T.R. Krishnan and I. Abraham. A rapid and sensitive high performance liquid chromatographic analysis of CFZ in plasma. Int. J. Lepr. 60: 549-555 (1992).
11. R.E. Mansfield. Tissue concentrations of CFZ in man. Am. J. Trop. Med. Hyg. 23: 1116-1119 (1974).
12. J.H. Peters, K.J. Hamme, and R. Gordon. Determination of CFZ in plasma by high-performance liquid chromatography. J. Chromatogr. 229: 503-508 (1982).
13. World Health Organization. Progress towards the elimination health problem. Wkly. Epidemiol. Rec. 68: 181-185 (1993).
14. J.L. Albiser and S.L. Moschella. CFZ: a review of its medical uses and mechanisms of action. J. Am. Acad. Dermatol. 32: 241-247 (1995).
15. R. O'Connor, J.F. O'Sullivan, and R. O'Kennedy. The pharmacology, metabolism, and chemistry of CFZ. Drug Met. Rev. 27: 591-614 (1995).
16. Z. Lanyi and J.P. Dubois. Determination of CFZ in human plasma by thin-layer chromatography. J. Chromatogr. 232: 219-223 (1982).
17. Z. Schaad-Lanyi, W. Dieterle, J.P.D.W. Theobald, and W. Vischer. Pharmacokinetics of clofazimine in healthy volunteers. Int. J. Lepr. 55: 9-15 (1987).
18. M. Gidoh and S. Tsutsumi. Determination of 3 main antileprosy drugs and their metabolites in serum by HPLC. J. Chromatogr. B 223: 379-392 (1981).
19. R. O'Connor, J.F. O'Sullivan, and R. O'Kennedy. Determination of serum and tissue levels of phenazines including CFZ. J. Chromatogr. B 681: 307-315 (1996).
20. P.S. Bonato and V.L. Lanchote. A rapid procedure for the purification of biological samples to be analyzed by high performance liquid chromatography. J. Liq. Chromatogr. 16: 2299-2308 (1993).